written by reader Looking for info on Manny Backus “Boston Biotech” Stock

By jstep8856, March 11, 2014

Hello Travis
Just saw a teaser about a ”Boston Biotech” stock that is poised to show 400 to 700% profits this year from Penny Stock gurus Manny Backus. Can you ”thinkolate” this one. Sounds pretty promising!
Thanks for your thoughts. They’re always appreciated!

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.



This site uses Akismet to reduce spam. Learn how your comment data is processed.

Inline Feedbacks
View all comments
March 12, 2014 1:30 am

Also have seen this one a lot..would love to know the ticker!

👍 6
March 12, 2014 3:53 am

Paul ,try BSX Boston scientific. I have seen that teased before but I don’t know of ant new developments..

Add a Topic
👍 7795
March 12, 2014 4:00 pm
👍 83
Andy Bell
Andy Bell
March 13, 2014 8:55 pm

Greenfire67 is 100% correct on Ziopharm. Manny Backus wrote up a major article
December 15, 2013 on it which you can read. He was promoting this stock on his Conscensus Picks which I still subscribe to. At that time he was advising subscribers
to buy below $4 and to sell at $9. The drug in question is AD-RTS-IL-12 which is in
phase two trials as of December 15, 2013. Also, the two partners that Ziopharm
is working with are Intrexon (XON) and Mesoblast. The insider guy in the tease that
bought 2,8577,000 shares for a cool ten million is Randall Kirk. They also issued 14.3 million shares last March which caused shares to plummet to $3.50 a stub. The title
of the article is “Ziopharm: Finally a Cure in the War on Cancer?” which you can access
by typing in ZIOP on the Finviz site, and scrolling down for this article below the stock
chart. I’m not sure but Dr. Karma might have something to say about it in the Benitech

Add a Topic
Add a Topic
Add a Topic

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info